Neoadjuvant nivolumab for resectable lung cancer

Biomarkers of pembrolizumab response in head and neck cancer

Phase I taselisib results and a cell-free DNA assay

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

A variety of approaches to measure the efficacy of PARP inhibitors

Development and clinical indications of PARP inhibitors

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Impact of microbiome on head and neck cancers

First-in-human trial results of RET targeted BLU-667

Treating RET alterations with novel therapy BLU-667

AKT inhibitors in research and application